Burning Rock Biotech Ltd. (BNR) - Gross Margin

Official company branding of Burning Rock Biotech Ltd. (BNR)

Burning Rock Biotech (BNR) is overcoming the market downturn in China by optimizing expenses amid pricing wars. The gross margin clearly demonstrates the long-term development vector, with the latest value recorded as 74.50. This NGS diagnostics leader is investing in AI-driven blood analysis. Simultaneously, Burning Rock Biotech (BNR) is implementing eco-friendly bio-waste disposal standards, reducing laboratory energy consumption to protect the environment.

BNR (Burning Rock Biotech Limited) Gross Profitability history from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Burning Rock (BNR)

- share price and consensus valuation forecast:
Fundamental valuation:BNR (Burning Rock Biotech Ltd.)
Mass-produced product of brbiotech.com

Burning Rock Biotech operates under severe pricing pressure and dependence on Chinese oncology diagnostics regulations. The current value of 74.50 reflects the revenue share minus direct production costs, allowing for an assessment of cost management efficiency amid a shortage of Western reagents, while the gross margin trend visualizes the business model's resilience to external risks.